BNT162b2 (Omi XBB.1.5)

BIOLOGICAL2 trials

Sponsors

BioNTech SE, Pfizer

Conditions

COVID-19Influenza, HumanSARS-CoV-2 Infection

Phase 2

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

CompletedNCT05997290

BioNTech SECOVID-19, SARS-CoV-2 Infection

Start: 2023-08-10End: 2025-03-13Updated: 2026-04-28

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

CompletedNCT06237049

PfizerCOVID-19, Influenza, Human, SARS-CoV-2 Infection

Start: 2024-01-31End: 2024-09-13Updated: 2025-09-30

Related Papers

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial

Infectious Diseases and Therapy2025-07-011 citations

A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old

Vaccine2025-02-245 citations

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial

Vaccines2024-07-0211 citations

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

Vaccines2024-01-2436 citations